APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antibody-drug Conjugates

Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased tissue.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased tissue.

Selected research

Market Outlook & Growth Opportunities

Global Antibody-drug Conjugates Market Outlook and Growth Opportunities 2026

22 December 2025195 pages

Choose your research edition.

Industry ResearchAntibody-drug Conjugates Industry Research Report 2026105 pages · $2,950 USDIndustry Growth & TrendsGlobal Antibody-drug Conjugates Industry Growth and Trends Forecast to 203274 pages · $3,450 USDMarket StructureGlobal Antibody-drug Conjugates Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032175 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antibody-drug Conjugates Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Antibody-drug Conjugates Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased tissue.

North America is the largest market with about 59% market share. Europe is follower, accounting for about 27% market share.

The key players are ImmunoGen, Seattle Genetics, Roche, Takeda etc. Takeda is the largest manufacturer with about 57% revenue market share.

Read the full market overview

This report provides an overview of the global Antibody-drug Conjugates market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antibody-drug Conjugates and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antibody-drug Conjugates sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Antibody-drug Conjugates market size, projected growth trends, production technologies, key applications, and end-use industries.

Antibody-drug Conjugates Segment by Company

ImmunoGen

Seattle Genetics

Roche

Takeda

Antibody-drug Conjugates Segment by Type

Adcetris

Kadcyla

Antibody-drug Conjugates Segment by Application

Breast Cancer

Lymphoma

Antibody-drug Conjugates Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Antibody-drug Conjugates status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Antibody-drug Conjugates market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Antibody-drug Conjugates significant trends, drivers, influence factors in global and regions.

6. To analyze Antibody-drug Conjugates competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antibody-drug Conjugates market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antibody-drug Conjugates and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antibody-drug Conjugates.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Antibody-drug Conjugates market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antibody-drug Conjugates industry.

Chapter 3: Detailed analysis of Antibody-drug Conjugates manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Antibody-drug Conjugates in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Antibody-drug Conjugates in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Antibody-drug Conjugates Industry Trends Table 2. Antibody-drug Conjugates Industry Drivers Table 3. Antibody-drug Conjugates Industry Opportunities and Challenges Table 4. Antibody-drug Conjugates Industry Restraints Table 5. Global Antibody-drug Conjugates Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Antibody-drug Conjugates Revenue Share by Company (2021-2026) Table 7. Global Antibody-drug Conjugates Sales Volume by Company (Kg) & (2021-2026) Table 8. Global Antibody-drug Conjugates Sales Volume Share by Company (2021-2026) Table 9. Global Antibody-drug Conjugates Average Price (USD/Kg) of Company (2021-2026) Table 10. Global Antibody-drug Conjugates Company Ranking, (2024-2026) & (USD Million) Table 11. Global Antibody-drug Conjugates Key Company Manufacturing Base & Headquarters Table 12. Global Antibody-drug Conjugates Company, Product Type & Application Table 13. Global Antibody-drug Conjugates Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Antibody-drug Conjugates by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Adcetris Table 18. Significant Companies of Kadcyla Table 19. Global Antibody-drug Conjugates Sales Volume by Type 2021 VS 2025 VS 2032 (Kg) Table 20. Global Antibody-drug Conjugates Sales Volume by Type (2021-2026) & (Kg) Table 21. Global Antibody-drug Conjugates Sales Volume by Type (2027-2032) & (Kg) Table 22. Global Antibody-drug Conjugates Sales Volume Share by Type (2021-2026) Table 23. Global Antibody-drug Conjugates Sales Volume Share by Type (2027-2032) Table 24. Global Antibody-drug Conjugates Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Antibody-drug Conjugates Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Antibody-drug Conjugates Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Antibody-drug Conjugates Sales Value Share by Type (2021-2026) Table 28. Global Antibody-drug Conjugates Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Breast Cancer Table 30. Significant Companies of Lymphoma Table 31. Global Antibody-drug Conjugates Sales Volume by Application 2021 VS 2025 VS 2032 (Kg) Table 32. Global Antibody-drug Conjugates Sales Volume by Application (2021-2026) & (Kg) Table 33. Global Antibody-drug Conjugates Sales Volume by Application (2027-2032) & (Kg) Table 34. Global Antibody-drug Conjugates Sales Volume Share by Application (2021-2026) Table 35. Global Antibody-drug Conjugates Sales Volume Share by Application (2027-2032) Table 36. Global Antibody-drug Conjugates Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Antibody-drug Conjugates Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Antibody-drug Conjugates Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Antibody-drug Conjugates Sales Value Share by Application (2021-2026) Table 40. Global Antibody-drug Conjugates Sales Value Share by Application (2027-2032) Table 41. Global Antibody-drug Conjugates Sales by Region: 2021 VS 2025 VS 2032 (Kg) Table 42. Global Antibody-drug Conjugates Sales by Region (2021-2026) & (Kg) Table 43. Global Antibody-drug Conjugates Sales Market Share by Region (2021-2026) Table 44. Global Antibody-drug Conjugates Sales by Region (2027-2032) & (Kg) Table 45. Global Antibody-drug Conjugates Sales Market Share by Region (2027-2032) Table 46. Global Antibody-drug Conjugates Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Antibody-drug Conjugates Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Antibody-drug Conjugates Sales Value Share by Region (2021-2026) Table 49. Global Antibody-drug Conjugates Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Antibody-drug Conjugates Sales Value Share by Region (2027-2032) Table 51. Global Antibody-drug Conjugates Market Average Price (USD/Kg) by Region (2021-2026) Table 52. Global Antibody-drug Conjugates Market Average Price (USD/Kg) by Region (2027-2032) Table 53. Global Antibody-drug Conjugates Sales by Country: 2021 VS 2025 VS 2032 (Kg) Table 54. Global Antibody-drug Conjugates Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Antibody-drug Conjugates Sales by Country (2021-2026) & (Kg) Table 56. Global Antibody-drug Conjugates Sales Market Share by Country (2021-2026) Table 57. Global Antibody-drug Conjugates Sales by Country (2027-2032) & (Kg) Table 58. Global Antibody-drug Conjugates Sales Market Share by Country (2027-2032) Table 59. Global Antibody-drug Conjugates Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Antibody-drug Conjugates Sales Value Market Share by Country (2021-2026) Table 61. Global Antibody-drug Conjugates Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Antibody-drug Conjugates Sales Value Market Share by Country (2027-2032) Table 63. ImmunoGen Company Information Table 64. ImmunoGen Business Overview Table 65. ImmunoGen Antibody-drug Conjugates Sales (Kg), Value (US$ Million), Price (USD/Kg) and Gross Margin (2021-2026) Table 66. ImmunoGen Antibody-drug Conjugates Product Portfolio Table 67. ImmunoGen Recent Development Table 68. Seattle Genetics Company Information Table 69. Seattle Genetics Business Overview Table 70. Seattle Genetics Antibody-drug Conjugates Sales (Kg), Value (US$ Million), Price (USD/Kg) and Gross Margin (2021-2026) Table 71. Seattle Genetics Antibody-drug Conjugates Product Portfolio Table 72. Seattle Genetics Recent Development Table 73. Roche Company Information Table 74. Roche Business Overview Table 75. Roche Antibody-drug Conjugates Sales (Kg), Value (US$ Million), Price (USD/Kg) and Gross Margin (2021-2026) Table 76. Roche Antibody-drug Conjugates Product Portfolio Table 77. Roche Recent Development Table 78. Takeda Company Information Table 79. Takeda Business Overview Table 80. Takeda Antibody-drug Conjugates Sales (Kg), Value (US$ Million), Price (USD/Kg) and Gross Margin (2021-2026) Table 81. Takeda Antibody-drug Conjugates Product Portfolio Table 82. Takeda Recent Development Table 83. Key Raw Materials Table 84. Raw Materials Key Suppliers Table 85. Antibody-drug Conjugates Distributors List Table 86. Antibody-drug Conjugates Customers List Table 87. Research Programs/Design for This Report Table 88. Authors List of This Report Table 89. Secondary Sources Table 90. Primary Sources List of Figures Figure 1. Antibody-drug Conjugates Product Image Figure 2. Global Antibody-drug Conjugates Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antibody-drug Conjugates Sales Value (2021-2032) & (US$ Million) Figure 4. Global Antibody-drug Conjugates Sales (2021-2032) & (Kg) Figure 5. Global Antibody-drug Conjugates Sales Average Price (USD/Kg) & (2021-2032) Figure 6. Global Antibody-drug Conjugates Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Adcetris Image Figure 10. Kadcyla Image Figure 11. Global Antibody-drug Conjugates Sales Volume by Type (2021 VS 2025 VS 2032) & (Kg) Figure 12. Global Antibody-drug Conjugates Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Antibody-drug Conjugates Sales Volume Share by Type (2021-2032) Figure 14. Global Antibody-drug Conjugates Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Antibody-drug Conjugates Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Antibody-drug Conjugates Sales Value Share by Type (2021-2032) Figure 17. Breast Cancer Image Figure 18. Lymphoma Image Figure 19. Global Antibody-drug Conjugates Sales Volume by Application (2021 VS 2025 VS 2032) & (Kg) Figure 20. Global Antibody-drug Conjugates Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Antibody-drug Conjugates Sales Volume Share by Application (2021-2032) Figure 22. Global Antibody-drug Conjugates Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Antibody-drug Conjugates Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Antibody-drug Conjugates Sales Value Share by Application (2021-2032) Figure 25. Global Antibody-drug Conjugates Sales by Region: 2021 VS 2025 VS 2032 (Kg) Figure 26. Global Antibody-drug Conjugates Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Antibody-drug Conjugates Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Antibody-drug Conjugates Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Antibody-drug Conjugates Sales Value (2021-2032) & (US$ Million) Figure 30. North America Antibody-drug Conjugates Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Antibody-drug Conjugates Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Antibody-drug Conjugates Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Antibody-drug Conjugates Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Antibody-drug Conjugates Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Antibody-drug Conjugates Sales Value (2021-2032) & (US$ Million) Figure 36. South America Antibody-drug Conjugates Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Antibody-drug Conjugates Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Antibody-drug Conjugates Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Antibody-drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Antibody-drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Antibody-drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Antibody-drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Antibody-drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Antibody-drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Antibody-drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Antibody-drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Antibody-drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Antibody-drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Antibody-drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Antibody-drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Antibody-drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Antibody-drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Antibody-drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Antibody-drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Antibody-drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Antibody-drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Antibody-drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Antibody-drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Antibody-drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Antibody-drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Antibody-drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Antibody-drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Antibody-drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Antibody-drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Antibody-drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Antibody-drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Antibody-drug Conjugates Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Antibody-drug Conjugates Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Adcetris
  • Kadcyla
Applications
  • Breast Cancer
  • Lymphoma
Companies covered
  • ImmunoGen
  • Seattle Genetics
  • Roche
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Antibody-drug Conjugates Sales Value (2021-2032)
  4. 1.2.2 Global Antibody-drug Conjugates Sales Volume (2021-2032)
  5. 1.2.3 Global Antibody-drug Conjugates Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Antibody-drug Conjugates Market Dynamics
  1. 2.1 Antibody-drug Conjugates Industry Trends
  2. 2.2 Antibody-drug Conjugates Industry Drivers
  3. 2.3 Antibody-drug Conjugates Industry Opportunities and Challenges
  4. 2.4 Antibody-drug Conjugates Industry Restraints
3 Antibody-drug Conjugates Market by Company
  1. 3.1 Global Antibody-drug Conjugates Company Revenue Ranking in 2025
  2. 3.2 Global Antibody-drug Conjugates Revenue by Company (2021-2026)
  3. 3.3 Global Antibody-drug Conjugates Sales Volume by Company (2021-2026)
  4. 3.4 Global Antibody-drug Conjugates Average Price by Company (2021-2026)
  5. 3.5 Global Antibody-drug Conjugates Company Ranking (2024-2026)
  6. 3.6 Global Antibody-drug Conjugates Company Manufacturing Base and Headquarters
  7. 3.7 Global Antibody-drug Conjugates Company Product Type and Application
  8. 3.8 Global Antibody-drug Conjugates Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Antibody-drug Conjugates Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Antibody-drug Conjugates Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Antibody-drug Conjugates Market by Type
  1. 4.1 Antibody-drug Conjugates Type Introduction
  2. 4.1.1 Adcetris
  3. 4.1.2 Kadcyla
  4. 4.2 Global Antibody-drug Conjugates Sales Volume by Type
  5. 4.2.1 Global Antibody-drug Conjugates Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Antibody-drug Conjugates Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Antibody-drug Conjugates Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Antibody-drug Conjugates Sales Value by Type
  9. 4.3.1 Global Antibody-drug Conjugates Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Antibody-drug Conjugates Sales Value by Type (2021-2032)
  11. 4.3.3 Global Antibody-drug Conjugates Sales Value Share by Type (2021-2032)
5 Antibody-drug Conjugates Market by Application
  1. 5.1 Antibody-drug Conjugates Application Introduction
  2. 5.1.1 Breast Cancer
  3. 5.1.2 Lymphoma
  4. 5.2 Global Antibody-drug Conjugates Sales Volume by Application
  5. 5.2.1 Global Antibody-drug Conjugates Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Antibody-drug Conjugates Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Antibody-drug Conjugates Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Antibody-drug Conjugates Sales Value by Application
  9. 5.3.1 Global Antibody-drug Conjugates Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Antibody-drug Conjugates Sales Value by Application (2021-2032)
  11. 5.3.3 Global Antibody-drug Conjugates Sales Value Share by Application (2021-2032)
6 Antibody-drug Conjugates Regional Sales and Value Analysis
  1. 6.1 Global Antibody-drug Conjugates Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antibody-drug Conjugates Sales by Region (2021-2032)
  3. 6.2.1 Global Antibody-drug Conjugates Sales by Region: 2021-2026
  4. 6.2.2 Global Antibody-drug Conjugates Sales by Region (2027-2032)
  5. 6.3 Global Antibody-drug Conjugates Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Antibody-drug Conjugates Sales Value by Region (2021-2032)
  7. 6.4.1 Global Antibody-drug Conjugates Sales Value by Region: 2021-2026
  8. 6.4.2 Global Antibody-drug Conjugates Sales Value by Region (2027-2032)
  9. 6.5 Global Antibody-drug Conjugates Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Antibody-drug Conjugates Sales Value (2021-2032)
  12. 6.6.2 North America Antibody-drug Conjugates Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Antibody-drug Conjugates Sales Value (2021-2032)
  15. 6.7.2 Europe Antibody-drug Conjugates Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Antibody-drug Conjugates Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Antibody-drug Conjugates Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Antibody-drug Conjugates Sales Value (2021-2032)
  21. 6.9.2 South America Antibody-drug Conjugates Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Antibody-drug Conjugates Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Antibody-drug Conjugates Sales Value Share by Country, 2025 VS 2032
7 Antibody-drug Conjugates Country-level Sales and Value Analysis
  1. 7.1 Global Antibody-drug Conjugates Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Antibody-drug Conjugates Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Antibody-drug Conjugates Sales by Country (2021-2032)
  4. 7.3.1 Global Antibody-drug Conjugates Sales by Country (2021-2026)
  5. 7.3.2 Global Antibody-drug Conjugates Sales by Country (2027-2032)
  6. 7.4 Global Antibody-drug Conjugates Sales Value by Country (2021-2032)
  7. 7.4.1 Global Antibody-drug Conjugates Sales Value by Country (2021-2026)
  8. 7.4.2 Global Antibody-drug Conjugates Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Antibody-drug Conjugates Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Antibody-drug Conjugates Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Antibody-drug Conjugates Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Antibody-drug Conjugates Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Antibody-drug Conjugates Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Antibody-drug Conjugates Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Antibody-drug Conjugates Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Antibody-drug Conjugates Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Antibody-drug Conjugates Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Antibody-drug Conjugates Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Antibody-drug Conjugates Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Antibody-drug Conjugates Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Antibody-drug Conjugates Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Antibody-drug Conjugates Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Antibody-drug Conjugates Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Antibody-drug Conjugates Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Antibody-drug Conjugates Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Antibody-drug Conjugates Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Antibody-drug Conjugates Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Antibody-drug Conjugates Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Antibody-drug Conjugates Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Antibody-drug Conjugates Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Antibody-drug Conjugates Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Antibody-drug Conjugates Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Antibody-drug Conjugates Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Antibody-drug Conjugates Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Antibody-drug Conjugates Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Antibody-drug Conjugates Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Antibody-drug Conjugates Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Antibody-drug Conjugates Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 ImmunoGen
  2. 8.1.1 ImmunoGen Company Information
  3. 8.1.2 ImmunoGen Business Overview
  4. 8.1.3 ImmunoGen Antibody-drug Conjugates Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 ImmunoGen Antibody-drug Conjugates Product Portfolio
  6. 8.1.5 ImmunoGen Recent Developments
  7. 8.2 Seattle Genetics
  8. 8.2.1 Seattle Genetics Company Information
  9. 8.2.2 Seattle Genetics Business Overview
  10. 8.2.3 Seattle Genetics Antibody-drug Conjugates Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Seattle Genetics Antibody-drug Conjugates Product Portfolio
  12. 8.2.5 Seattle Genetics Recent Developments
  13. 8.3 Roche
  14. 8.3.1 Roche Company Information
  15. 8.3.2 Roche Business Overview
  16. 8.3.3 Roche Antibody-drug Conjugates Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Roche Antibody-drug Conjugates Product Portfolio
  18. 8.3.5 Roche Recent Developments
  19. 8.4 Takeda
  20. 8.4.1 Takeda Company Information
  21. 8.4.2 Takeda Business Overview
  22. 8.4.3 Takeda Antibody-drug Conjugates Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Takeda Antibody-drug Conjugates Product Portfolio
  24. 8.4.5 Takeda Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Antibody-drug Conjugates Value Chain Analysis
  2. 9.1.1 Antibody-drug Conjugates Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Antibody-drug Conjugates Sales Mode & Process
  6. 9.2 Antibody-drug Conjugates Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Antibody-drug Conjugates Distributors
  9. 9.2.3 Antibody-drug Conjugates Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst